Vascular Access division info

Discussion in 'AngioDynamics' started by anonymous, Jun 5, 2019 at 11:41 AM.

  1. anonymous

    anonymous Guest

    Looking at a vascular Access TM role. 170k at plan. How's the division as a whole? Can't seem to find too many reviews on Biim ultrasound. Any insight to this business unit would be great. Thank you
     

  2. anonymous

    anonymous Guest

    What territory?
     
  3. anonymous

    anonymous Guest

    New England
     
  4. anonymous

    anonymous Guest

    170k is attainable, but there are 5 buckets. You make up for missing a bucket with overage in another. Biim ultrasound is a new product, with a new version coming soon. Priced well, concept hits, but original was lacking in image quality.
     
  5. anonymous

    anonymous Guest

    Ask yourself why the territory is open. Do your homework.
     
  6. anonymous

    anonymous Guest

    Great technologies. Subpar upper leadership. Region Managers are solid but somehow I feel that they spend most of their time just buffering the Salesforce from the boneheads above. Comp plan is a stone cold joke considering the obstacles and amount of work necessary to succeed in this division. It’s just not worth it. Corporate accounts team is a skeleton crew. Getting on contract takes an act of god. And if you aren’t on contract good luck selling anything. Can and does it happen? Sure. But it’s a rarity.

    That’s the worst part about the VA division. You have a leadership team that all came from Covidien/Medtronic trying to run a $400m company like a $20b company. It just doesn’t work like that. When you’re small, you need talent to succeed. The only way get and keep talent is to pay them. It’s really to bad because I think objectively the products are mostly best in class. Honestly I’m surprised that this division hasn’t been broken up and sold off already.
     
  7. anonymous

    anonymous Guest

    Spot on. Oncology is no different. Sales are abysmal. Leadership thought they could treat reps like shit, not pay them and hire replacements. Well, how’s that working out ? Millions off the “number”. Stock in the dump. It’s almost penny stock. Turnover turnover and more turnover. This is the end. Keep replacing and replacing with the bottom of the barrel. I left while I still had self esteem.
     
  8. anonymous

    anonymous Guest

    Best in class yet Bard is market leader by a large margin, why?